International AIDS Vaccine Initiative (IAVI)
IAVI is a nonprofit scientific research organization dedicated to developing vaccines and antibodies for HIV, tuberculosis, and emerging infectious diseases. Their mission is to translate scientific discoveries into affordable, globally accessible public health solutions, aiming for a world where all people have equitable access to innovative vaccines and therapeutics.
Industries
N/A
Nr. of Employees
small (1-50)
International AIDS Vaccine Initiative (IAVI)
125 Broad Street, 9th Floor, New York, NY 10004, USA
International AIDS Vaccine Initiative (IAVI) is currently seeking investment
International AIDS Vaccine Initiative (IAVI) is seeking a series-a investment in the range of 5m-20m
Products
Replicating viral-vector vaccine candidates for hemorrhagic and emerging viruses
Clinical- and preclinical-stage vaccine candidates developed using replicating viral-vector platforms for pathogens such as Lassa fever, Ebola and Marburg viruses, and SARS-CoV-2; advanced into preclinical testing and clinical evaluation depending on candidate.
Live-attenuated and nucleic-acid tuberculosis vaccine candidates
Tuberculosis vaccine candidates including live-attenuated constructs and nucleic-acid-encoded antigen constructs advanced in preclinical and clinical development to improve protection in adolescents and adults.
Germline-targeting immunogen candidates delivered via nucleic-acid and nanoparticle platforms
Engineered immunogens designed to engage precursor B cells delivered in nucleic-acid or protein nanoparticle formats and evaluated in clinical studies to prime broadly neutralizing antibody lineages.
Replicating viral-vector vaccine candidates for hemorrhagic and emerging viruses
Clinical- and preclinical-stage vaccine candidates developed using replicating viral-vector platforms for pathogens such as Lassa fever, Ebola and Marburg viruses, and SARS-CoV-2; advanced into preclinical testing and clinical evaluation depending on candidate.
Live-attenuated and nucleic-acid tuberculosis vaccine candidates
Tuberculosis vaccine candidates including live-attenuated constructs and nucleic-acid-encoded antigen constructs advanced in preclinical and clinical development to improve protection in adolescents and adults.
Germline-targeting immunogen candidates delivered via nucleic-acid and nanoparticle platforms
Engineered immunogens designed to engage precursor B cells delivered in nucleic-acid or protein nanoparticle formats and evaluated in clinical studies to prime broadly neutralizing antibody lineages.
Services
One-stop shop offering end-to-end product development
Staff has several years of industry experience in each aspect of development
Experience translating discoveries through product development. Core services include deep experience across the full spectrum from preclinical development through translational medicine, process development and manufacturing, quality assurance, regulator affairs, clinical development (especially in Africa) and market access.
One-stop shop offering end-to-end product development Staff has several years of industry experience in each aspect of development Experience translating discoveries through product development. Core services include deep experience across the full spectrum from preclinical development through translational medicine, process development and manufacturing, quality assurance, regulator affairs, clinical development (especially in Africa) and market access.
Expertise Areas
- Vaccine and antibody discovery
- Monoclonal antibody isolation and engineering
- Preclinical models and challenge studies (small animals and nonhuman primates)
- Clinical trial design and operations, including discovery-medicine trials
Key Technologies
- Replicating viral-vector vaccine platforms
- mRNA lipid nanoparticle (mRNA-LNP) vaccine platforms
- Protein nanoparticle display for immunogen multivalency
- High-resolution structural biology (cryo-electron microscopy)
Key People
Mark Feinberg
President and CEO
Kara Bickman
Chief Development Officer
John Heinrichs
Vice President and Head of Discovery Science
Kundai Chinyenze
IAVI Africa Director
Shelly Malhotra
Vice President, Global Access and External Affairs
Mark Feinberg
President and CEO
Kara Bickman
Chief Development Officer
John Heinrichs
Vice President and Head of Discovery Science
Kundai Chinyenze
IAVI Africa Director
Shelly Malhotra
Vice President, Global Access and External Affairs
News & Updates
Discovery medicine trials are underway to evaluate several HIV vaccine immunogens designed to prime the immune system to make broadly neutralizing antibodies.
Quarraisha and Salim Abdool Karim received the 2024 Lasker-Bloomberg Public Service Award for their work on HIV prevention, treatment, and advocacy.
The AIDS 2026 conference in Rio de Janeiro put a sharp focus on access to innovation, especially with regard to new long-acting HIV prevention tools and future vaccines. Our team of scientists, communicators, community engagement specialists, and partnership managers all had their own takeaways across a spectrum of topics.
WHO identifies rVSV-based candidate as a top priority amid growing Ebola epidemic with no approved countermeasures.
Trial to generate foundational human safety and immunogenicity data, advancing a vaccine platform suited for rapid outbreak response.
New study published in Nature shows for the first time elicitation of broadly neutralizing antibodies to HIV in a stringent animal model.
Discovery medicine trials are underway to evaluate several HIV vaccine immunogens designed to prime the immune system to make broadly neutralizing antibodies.
Quarraisha and Salim Abdool Karim received the 2024 Lasker-Bloomberg Public Service Award for their work on HIV prevention, treatment, and advocacy.
The AIDS 2026 conference in Rio de Janeiro put a sharp focus on access to innovation, especially with regard to new long-acting HIV prevention tools and future vaccines. Our team of scientists, communicators, community engagement specialists, and partnership managers all had their own takeaways across a spectrum of topics.
WHO identifies rVSV-based candidate as a top priority amid growing Ebola epidemic with no approved countermeasures.
Trial to generate foundational human safety and immunogenicity data, advancing a vaccine platform suited for rapid outbreak response.
New study published in Nature shows for the first time elicitation of broadly neutralizing antibodies to HIV in a stringent animal model.